Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | Key Players are Bio-Rad Laboratories, Biocept Inc., Guardant Health, Illumina, Inc. and others

According to a research report published by Spherical Insights & Consulting, The Global Liquid Biopsy Market Size is to Grow from USD 8.50 Billion in 2022 to USD 25.24 Billion By 2032, at a Compound Annual Growth Rate CAGR of 11.5% during the forecast period.

Comprehensive historical analysis of global market for Liquid Biopsy Market has thoroughly analyzed in this report. It offers data and insights from 2018-2021, and provides extensive market forecasts from 2022-2032 by region/country and subsectors. It covers the price, sales volume, revenue, historical growth, gross margin, and future outlooks for the Global Liquid Biopsy Market.

Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/2471

Market Overview
A revolutionary non-invasive medical technique called liquid biopsy analyzes a variety of biomarkers present in a patient's blood or other body fluids to enable early cancer detection and surveillance. Liquid biopsies offer a less risky and easier way to obtain vital genetic and molecular information about malignancies than traditional tissue biopsies, which can be invasive and constrained by tumor accessibility. Through the identification of circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other macromolecules, liquid biopsy provides information about a tumor's genetic alterations, response to therapy, and potential for metastasis.

The global Liquid Biopsy Market is witnessing robust growth due to:
>>The rising number of cancer cases worldwide, with over 20 million new cancer diagnoses expected annually by 2030 driving demand for non-invasive diagnostic tools like liquid biopsies.

>>Increasing demand for minimally invasive procedures that allow for early cancer detection, real-time monitoring of tumor dynamics, and better patient compliance compared to traditional tissue biopsies.

>>Technological innovations in circulating tumor DNA (ctDNA), exosome analysis, and next-generation sequencing (NGS), enabling more accurate, faster, and comprehensive detection of cancer biomarkers through blood and other body fluids.

Browse key industry insights spread across 200 pages with 120 Market data tables and figures & charts from the report on the Global Liquid Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Technology (NGS, PCR, FISH, and Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, and Data Analysis), By Usage (RUO and Clinical), By Types of Sample (Blood, Urine, Saliva, and Cerebrospinal Fluid), By Circulating Biomarker (Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes & Extracellular Vesicles, and Others), By Products (Test/Services, Kits & Consumable, and Instruments), By Indication Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, and Others), By Clinical Application (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, and Diagnosis & Screening), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 - 2032.

The NGS segment had about 52.8% of the market in 2022.

The global liquid biopsy market is divided into several segments based on technology, including PCR, FISH, and NGS. Because of its remarkable ability to identify and analyze genetic abnormalities and modifications, the NGS (Next-Generation Sequencing) sector has maintained the biggest market share in the liquid biopsy industry. High-throughput sequencing of circulating tumor DNA and other indicators is made possible by NGS, which delivers accurate and thorough insights into cancer profiles. NGS is the go-to option for liquid biopsy testing because of its capacity to process numerous samples at once and quickly produce vast volumes of genetic data.

Throughout the forecast period, the blood sector had the greatest market.

The global liquid biopsy market is divided into four segments based on the kind of sample: blood, urine, saliva, and cerebrospinal fluid. Due in large part to its non-invasiveness and simplicity of sample collection, the blood segment dominated the liquid biopsy market during the projection period. A quick and easy way to find and examine circulating tumor cells (CTCs) and cell-free DNA (cfDNA) is through blood-based liquid biopsies, which can provide important details about the course of cancer, the effectiveness of treatment, and genetic alterations.

Buy Now: https://www.sphericalinsights.com/checkout/2471

Over the forecast period, Asia-Pacific is expected to develop at the quickest CAGR of over 11.7%.

Due to the growing incidence of cancer and an aging population, which generate a high demand for early diagnosis and precise monitoring solutions, the liquid biopsy market is anticipated to develop at the quickest rate in Asia-Pacific over the course of the projected period. Growing expenditures on research capacity and healthcare infrastructure have made it easier for cutting-edge medical technology, including liquid biopsy, to be adopted.

Due to the growing incidence of cancer and an aging population, which generate a high demand for early diagnosis and precise monitoring solutions, the liquid biopsy market is anticipated to develop at the quickest rate in Asia-Pacific over the course of the projected period. Growing expenditures on research capacity and healthcare infrastructure have made it easier for cutting-edge medical technology, including liquid biopsy, to be adopted.

Leading players of Liquid Biopsy Market including:
• Bio-Rad Laboratories
• Biocept Inc.
• Guardant Health
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.
• Others

Market Challenges: Liquid Biopsy Market
1. High Cost of Testing and Limited Reimbursement
>>Liquid biopsy tests can cost hundreds to thousands of dollars per sample, depending on the technology and scope (e.g., multi-cancer detection).

2. Regulatory Uncertainty
>>While a few liquid biopsy tests have gained approval (e.g., for EGFR mutations in lung cancer), most applications still lack clear regulatory pathways.

3. Limited Sensitivity and Specificity
>>Despite rapid improvements, current technologies may still struggle to accurately detect low levels of biomarkers, especially in early-stage or low-tumor-burden cancers.

4. Lack of Standardization in Sample Collection and Processing
>>There is no unified global protocol for pre-analytical handling of samples, which affects test accuracy, reproducibility, and clinical reliability.

Research Objectives: Liquid Biopsy Market
>>To determine the current market size, CAGR, and future growth potential of the global liquid biopsy market, segmented by cancer type, biomarker type, end user, and geography (2024-2033).

>>To analyze the key drivers fueling market growth, including the increasing global cancer burden, rising demand for minimally invasive diagnostics, and advancements in biomarker detection technologies.

>>To assess the clinical and commercial viability of liquid biopsy tests for various applications such as early cancer detection, treatment selection, therapy monitoring, and recurrence tracking.

>>To evaluate the role of emerging technologies (e.g., NGS, ddPCR, AI-powered analytics, microfluidics, and multi-omics) in improving test accuracy, speed, and scalability.

>>To identify major challenges and limitations, including sensitivity/specificity constraints, lack of standardization, cost and reimbursement issues, and regulatory hurdles.

Market Segment
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global liquid biopsy market based on the below-mentioned segments:

Liquid Biopsy Market, By Technology
• NGS
• PCR
• FISH
• Others

Liquid Biopsy Market, By Workflow
• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis

Liquid Biopsy Market, By Usage
• RUO
• Clinical

Liquid Biopsy Market, By Type of Sample
• Blood
• Urine
• Saliva
• Cerebrospinal Fluid

Liquid Biopsy Market, By Circulating Biomarker
• Circulating Tumor Cells
• Cell-free DNA
• Circulating Cell-Free RNA
• Exosomes & Extracellular Vesicles
• Others

Liquid Biopsy Market, By Products
• Test/Services
• Kits & Consumable
• Instruments

Liquid Biopsy Market, By Indication Type
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Others

Liquid Biopsy Market, By Clinical Application
• Treatment Monitoring
• Prognosis & Recurrence Monitoring
• Treatment Selection
• Diagnosis & Screening

Regional Segment Analysis of the Global Liquid Biopsy Market
• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America)
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

What's covered in the report?
1. Overview of the Liquid Biopsy Market.
2. The current and forecasted regional (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa) market size data for the Liquid Biopsy Market, based on segment.
3 Liquid Biopsy Market trends.
4. Liquid Biopsy Market drivers.
5. Analysis of major company profiles.

PESTLE Analysis: Liquid Biopsy Market
 Political Factors
Regulatory scrutiny & evolving approval frameworks
>>FDA, EMA, and other agencies are establishing guidelines for liquid biopsy-based diagnostics. Although select applications (e.g., ctDNA for EGFR mutations) have gained approval, many multi-cancer panels await further validation

 Economic Factors
Rapid market growth with strong investment
>>Valued at USD 3.65 B in 2024 and growing at 11-12% CAGR, liquid biopsy is projected to reach USD 7-11 B by 2029-2033

 Social Factors
Growing cancer incidence & patient preference for non-invasive testing
>>With nearly 10 million cancer deaths in 2022, demand for safer, repeatable diagnostics is rising

 Technological Factors
Advancements in NGS, PCR, and microfluidics
>>Techniques enabling ctDNA, CTC, cfDNA, and exosome detection are improving, driving broader clinical use CTCs alone form 70% of current market revenue

 Legal Factors
Absence of global standardization and harmonized protocols
>>Variability in pre-analytical sample collection and processing standards hampers clinical adoption and comparability

 Environmental Factors
Minimal direct environmental risks
>>Unlike imaging or invasive biopsy, liquid biopsy uses small samples and generates limited waste.

Table of Content (TOC)
• Introduction
1. Objectives of the Study
2. Market Definition
3. Research Scope
• Research Methodology and Assumptions
• Executive Summary
• Premium Insights
1. Porter's Five Forces Analysis
2. Value Chain Analysis
3. Top Investment Pockets
1. Market Attractiveness Analysis By Product Type
2. Market Attractiveness Analysis By Type
3. Market Attractiveness Analysis By Segment Type
4. Market Attractiveness Analysis By Region
4. Industry Trends
• Market Dynamics
1. Market Evaluation
2. Drivers
1. Increasing development in sector
3. Restraints
4. Opportunities
5. Challenges
• Global Liquid Biopsy Market Analysis and Projection, By Product Type
• Global Liquid Biopsy Market Analysis and Projection, By Type
• Global Liquid Biopsy Market Analysis and Projection, By Segment Type
• Global Liquid Biopsy Market Analysis and Projection, By Regional Analysis
1. Segment Overview
2. North America
1. U.S.
2. Canada
3. Mexico
3. Europe
1. Germany
2. France
3. U.K.
4. Italy
5. Spain
4. Asia-Pacific
1. Japan
2. China
3. India
5. South America
1. Brazil
6. Middle East and Africa
1. UAE
2. South Africa
• Global Liquid Biopsy Market-Competitive Landscape
1. Overview
2. Market Share of Key Players in the Global Liquid Biopsy Market
1. Global Company Market Share
2. North America Company Market Share
3. Europe Company Market Share
4. APAC Company Market Share
3. Competitive Situations and Trends
1. Coverage Launches and Developments
2. Partnerships, Collaborations, and Agreements
3. Mergers & Acquisitions
4. Expansions
• Company Profiles
1. Company1
1. Business Overview
2. Company Snapshot
3. Company Market Share Analysis
4. Company Coverage Portfolio
5. Recent Developments
6. SWOT Analysis
2. Company2
1. Business Overview
2. Company Snapshot
3. Company Market Share Analysis
4. Company Coverage Portfolio
5. Recent Developments
6. SWOT Analysis
3. Company3
1. Business Overview
2. Company Snapshot
3. Company Market Share Analysis
4. Company Coverage Portfolio
5. Recent Developments
6. SWOT Analysis

Industry Related Reports
Global Cell Therapy Biomanufacturing Market Size
https://www.sphericalinsights.com/reports/cell-therapy-biomanufacturing-market

Global Bone-Cutting Technology Market Size
https://www.sphericalinsights.com/reports/bone-cutting-technology-market

Global Fixed Human Anesthesia Workstation Market Size
https://www.sphericalinsights.com/reports/fixed-human-anesthesia-workstation-market

About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.

CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Follow Us: LinkedIn | Facebook | Twitter

This release was published on openPR.